16 November 2026 | Monday | News
Image Source: Public Domain
The FDA New Drug Application (NDA) and EMA Marketing Authorization Application (MAA) submissions for etavopivat are based on data from the Phase 3 HIBISCUS trial showing efficacy and safety results in adolescents and adults living with sickle cell disease1
Sickle cell disease is a progressive, life-threatening, debilitating blood disease with limited disease-modifying therapeutic options that affects an estimated 100,000 Americans, 110,000 Europeans – and around 8 million people worldwide2-4
Etavopivat is designed to help reduce the sickling of red blood cells and is being evaluated for potential improvement of hemoglobin response (>1 g/dL) rate at week 24 and the reduction of annualized 'vaso-occlusive crises' (VOCs) rates at week 521
Novo Nordisk announced the submissions of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) and a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for etavopivat, an investigational, once-daily, orally available, selective activator of pyruvate kinase red blood cell isozyme (PKR), for the treatment of adolescents and adults (aged 12 years and older) living with sickle cell disease (SCD). If approved, etavopivat could offer a new approach to treating SCD as a disease-modifying therapy.
The FDA has previously granted etavopivat Fast Track, Rare Pediatric Disease and Orphan Drug designations and is expected to take action on the NDA in 2027. Etavopivat was also granted Orphan Drug designation by the European Commission who is expected to take action on the MAA in 2027. A MAA is the formal application for seeking approval to market a medicine in the European Union (EU).
"For people living with sickle cell disease, severe vaso-occlusive crises and other symptoms can have a profound impact on everyday life, and treatment options remain limited," said Martin Holst Lange, executive vice president, chief scientific officer and head of Research & Development at Novo. "If approved, we are hopeful that etavopivat can provide a new disease-modifying treatment option for people living with sickle cell disease, and we will continue to work alongside the community to help advance health equity and overcome the longstanding disparities that impact those affected by this disease."
The NDA and MAA submissions are grounded in the results from the HIBISCUS study program, which was designed to establish the efficacy and safety profile of etavopivat, and evaluated the annualized rate of vaso-occlusive crises (VOCs) at week 52 and hemoglobin response (>1 g/dL) rate at week 24 compared to placebo, in adults and adolescents living with SCD. Participants were also allowed to receive standard of care treatment throughout the trial.1 In topline results announced in April 2026, etavopivat showed a 27% reduction in VOCs and a ~4-month delay to the first VOC compared to placebo. More detailed results from the HIBISCUS phase 3 trial will be presented at a future scientific conference and published in a peer-reviewed journal.
© 2026 Biopharma Boardroom. All Rights Reserved.